^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Excerpt:
Of particular note is a patient with both an EGFR exon 19 deletion and a KRAS mutation; this patient did well with erlotinib therapy, achieving stable disease for 25.8 months.
DOI:
10.1158/1078-0432.CCR-09-0888